Wall Street brokerages expect Menlo Therapeutics (NASDAQ:MNLO) to report earnings of ($0.68) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Menlo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.65). The firm is scheduled to announce its next quarterly earnings results on Wednesday, June 27th.

On average, analysts expect that Menlo Therapeutics will report full-year earnings of ($3.20) per share for the current financial year, with EPS estimates ranging from ($3.34) to ($3.05). For the next financial year, analysts forecast that the company will report earnings of ($3.63) per share, with EPS estimates ranging from ($4.11) to ($3.14). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Menlo Therapeutics.

How to Become a New Pot Stock Millionaire

Menlo Therapeutics (NASDAQ:MNLO) last released its earnings results on Wednesday, March 28th. The company reported ($1.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($1.11). The firm had revenue of $2.78 million during the quarter.

A number of equities analysts recently issued reports on the company. Piper Jaffray assumed coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set an “overweight” rating and a $48.00 price objective for the company. Jefferies Group assumed coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set a “buy” rating and a $41.00 price objective for the company. Guggenheim assumed coverage on Menlo Therapeutics in a report on Monday, February 19th. They set a “buy” rating and a $52.00 price objective for the company. Finally, JMP Securities assumed coverage on Menlo Therapeutics in a report on Tuesday, February 20th. They set an “outperform” rating and a $44.00 price objective for the company.

In other news, major shareholder Vivo Capital Surplus Fund Viii bought 294,118 shares of the stock in a transaction on Thursday, January 25th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $5,000,006.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of NASDAQ MNLO traded up $0.02 during trading hours on Thursday, hitting $9.53. 47,599 shares of the company traded hands, compared to its average volume of 237,182. Menlo Therapeutics has a 12 month low of $7.94 and a 12 month high of $39.86.

WARNING: “-$0.68 Earnings Per Share Expected for Menlo Therapeutics (MNLO) This Quarter” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/04/17/0-68-earnings-per-share-expected-for-menlo-therapeutics-mnlo-this-quarter.html.

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc, a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.